Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

Melinta Therapeutics, Inc.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Established: 2000-01-01

Employees: 290

Market Cap: -

Website: http://melinta.com

Clinical Trials

A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Meropenem-Vaborbactam in Children With Complicated Urinary Tract Infection, Including Acute Pyelonephritis

Phase 2

Recruiting

Conditions: Acute Pyelonephritis
Complicated Urinary Tract Infection

Interventions: Drug: Meropenem-Vaborbactam
Drug: Antibiotics

First Posted Date: 2024-11-04

Last Posted Date: 2025-06-29

Lead Sponsor: Rempex (a wholly owned subsidiary of Melinta Therapeutics, LLC)

Target Recruit Count: 66

Registration Number: NCT06672978

Locations: 🇺🇸
Children's Hospital of Orange County, Orange, California, United States
🇧🇬
Multiprofile Hospital for Active Treatment "Sv. Ivan Rilski - 2003" OOD, Department of Pediatric Diseases, Dupnitsa, Bulgaria
🇧🇬
University Multipurpose Hospital for Active Treatment "Sveti Georgi", Pediatrics Clinic, Plovdiv, Bulgaria

and more 8 locations

A Study Comparing the Bioavailability of a Taste-masked Delafloxacin Powder for Oral Suspension With the Delafloxacin Tablet in Healthy Adults

Phase 1

Terminated

Conditions: Healthy

Interventions: Drug: Delafloxacin
Drug: Delafloxacin Powder

First Posted Date: 2024-09-25

Last Posted Date: 2024-11-25

Lead Sponsor: Melinta Therapeutics, Inc.

Target Recruit Count: 16

Registration Number: NCT06612255

Locations: 🇬🇧
Quotient Sciences, Ruddington, Nottingham, United Kingdom

Relative Exposure and Safety Study of Kimyrsa in ABSSSI Patients

Phase 1

Completed

Conditions: Acute Bacterial Skin and Skin Structure Infection

Interventions: Drug: Kimyrsa
Drug: Current Formulation of Oritavancin

First Posted Date: 2019-03-14

Last Posted Date: 2021-04-13

Lead Sponsor: Melinta Therapeutics, Inc.

Target Recruit Count: 102

Registration Number: NCT03873987

Locations: 🇺🇸
ML-ORI-102 Study Site, Somers Point, New Jersey, United States

Evaluate Safety and Pharmacokinetic To Assess Bronchopulmonary Disposition of Intravenous Delafloxacin in Healthy Adults

Phase 1

Completed

Conditions: Pneumonia

Interventions: Drug: Delafloxacin

First Posted Date: 2018-05-23

Last Posted Date: 2018-08-15

Lead Sponsor: Melinta Therapeutics, Inc.

Target Recruit Count: 30

Registration Number: NCT03534622

Locations: 🇺🇸
Pulmonary Associates, Phoenix, Arizona, United States

A Retrospective Observational Study to Evaluate the Utilization, Outcomes, and Adverse Events in Participants Treated With Orbactiv® (Oritavancin) for Infections Caused by Gram Positive Bacteria in a Real World Setting

Completed

Conditions: Gram-Positive Bacterial Infections

Interventions: Drug: Oritavancin

First Posted Date: 2017-05-18

Last Posted Date: 2018-03-12

Lead Sponsor: Melinta Therapeutics, Inc.

Target Recruit Count: 325

Registration Number: NCT03159403

Locations: 🇺🇸
Birmingham Infectious Disease and Infusion, Birmingham, Alabama, United States
🇺🇸
Santa Barbara Cottage Hospital, Santa Barbara, California, United States
🇺🇸
Florida Infectious Disease Care, Fort Myers, Florida, United States

and more 18 locations

A Study of Meropenem-Vaborbactam Versus Piperacillin/Tazobactam in Participants With Hospital-Acquired and Ventilator-Associated Bacterial Pneumonia

Phase 3

Withdrawn

Conditions: Hospital-Acquired Bacterial Pneumonia
Hospital-Acquired Pneumonia
Ventilator-Associated Pneumonia
Ventilator-Associated Bacterial Pneumonia

Interventions: Drug: Piperacillin/Tazobactam
Drug: Meropenem-Vaborbactam

First Posted Date: 2016-12-30

Last Posted Date: 2019-01-11

Lead Sponsor: Melinta Therapeutics, Inc.

Registration Number: NCT03006679

Study to Compare Delafloxacin to Moxifloxacin for the Treatment of Adults With Community-acquired Bacterial Pneumonia

Phase 3

Completed

Conditions: Community Acquired Bacterial Pneumonia

Interventions: Drug: Moxifloxacin
Drug: Delafloxacin
Drug: Linezolid

First Posted Date: 2016-02-10

Last Posted Date: 2020-02-27

Lead Sponsor: Melinta Therapeutics, Inc.

Target Recruit Count: 860

Registration Number: NCT02679573

Locations: 🇺🇦
Melinta 306 Study Site, Zhytomyr, Ukraine

Safety and Efficacy of Solithromycin in Adolescents and Children With Community-Acquired Bacterial Pneumonia

Phase 2

Terminated

Conditions: Community-acquired Bacterial Pneumonia

Interventions: Drug: Solithromycin
Drug: Standard of Care

First Posted Date: 2015-11-16

Last Posted Date: 2019-01-03

Lead Sponsor: Melinta Therapeutics, Inc.

Target Recruit Count: 97

Registration Number: NCT02605122

Safety and Efficacy of Solithromycin in the Treatment of Nonalcoholic Steatohepatitis Without Cirrhosis

Phase 2

Completed

Conditions: Nonalcoholic Steatohepatitis

Interventions: Drug: solithromycin

First Posted Date: 2015-07-29

Last Posted Date: 2017-03-21

Lead Sponsor: Melinta Therapeutics, Inc.

Target Recruit Count: 10

Registration Number: NCT02510599

Locations: 🇺🇸
Case Western University Hospitals, Cleveland, Ohio, United States

Study to Evaluate the Effect of Delafloxacin on the Pharmacokinetics of Midazolam in Healthy Subjects

Phase 1

Completed

Conditions: VA Drug Interactions

Interventions: Drug: Midazolam
Drug: Delafloxacin

First Posted Date: 2015-07-22

Last Posted Date: 2016-12-16

Lead Sponsor: Melinta Therapeutics, Inc.

Target Recruit Count: 22

Registration Number: NCT02505997

Locations: 🇺🇸
PPD Development, LP, Austin, Texas, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy